맞춤형 의료 바이오마커 시장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Personalized Medicine Biomarkers Market, valued at USD 15.9 billion in 2023, is set for remarkable growth with a projected CAGR of 15.1% from 2024 to 2032. This market expansion is driven by increasing chronic disease rates, advancements in genomics and proteomics, and the shift toward customized healthcare solutions. As healthcare becomes more patient-centered, personalized medicine biomarkers revolutionize treatment by enabling precise, targeted care. Significant progress in genomic sequencing and molecular diagnostics has enhanced the ability to identify disease-specific biomarkers, enabling more tailored treatment strategies. Pharmaceutical companies are harnessing these advancements to develop precision therapies with greater efficacy and reduced side effects and improve patient outcomes and adherence.

Segmented by biomarker type, the market includes genomic, proteomic, and metabolic biomarkers, among others. Genomic biomarkers led with a substantial USD 6.6 billion in revenue in 2023, underscoring their importance in disease detection, risk evaluation, and treatment optimization. Genomic markers, derived from gene analysis, provide insights into genetic predispositions and can predict how patients respond to specific treatments, particularly in fields like oncology. These insights allow healthcare providers to devise more effective, patient-specific therapies, bolstering treatment success rates and improving quality of life.

In terms of applications, the market is divided into early detection/screening, diagnosis, treatment selection, and monitoring. The diagnostic segment held a 34.1% share in 2023 and remains essential for early and accurate disease detection. Leveraging various biomarkers, such as genetic, proteomic, and metabolomic, personalized diagnostics offer clinicians valuable insights into disease stages and potential therapeutic responses. This is especially critical in managing conditions in oncology, cardiology, and neurology, where timely intervention is key.

In the U.S., the personalized medicine biomarkers market is anticipated to grow at a 15% CAGR, reaching USD 21.1 billion by 2032. This growth is supported by the country's advanced healthcare infrastructure, significant R&D investments, and proactive adoption of precision medicine. Federal initiatives are accelerating research and fostering data integration, while the prevalence of chronic diseases continues to drive biomarker demand. Additionally, collaboration between top pharmaceutical and biotech companies, with academic and government institutions is spurring innovations in biomarker development. Rising patient awareness and demand for personalized treatment options fuel this trend, with diagnostics and companion therapeutics seeing increased utilization to enhance treatment outcomes and minimize adverse effects.Overall, the personalized medicine biomarkers market is positioned for substantial expansion, as precision diagnostics and targeted therapies continue to reshape patient care, making treatment more efficient and aligned with individual patient needs.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Advances in genomics and proteomics
    • 3.2.1.2 Rising prevalence of chronic diseases
    • 3.2.1.3 Growing demand for targeted therapies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High development costs
    • 3.2.2.2 Regulatory complexities
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Future market trends
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates & Forecast, By Biomarker Type, 2021-2032 ($ Mn)

• 5.1 Key trends
• 5.2 Genomic
• 5.3 Proteomics
• 5.4 Metabolic
• 5.5 Other biomarker types

Chapter 6 Market Estimates & Forecast, By Application, 2021-2032 ($ Mn)

• 6.1 Key trends
• 6.2 Early detection/screening
• 6.3 Diagnosis
• 6.4 Treatment selection
• 6.5 Monitoring
• 6.6 Other applications

Chapter 7 Market Estimates & Forecast, By Disease Indication, 2021-2032 ($ Mn)

• 7.1 Key trends
• 7.2 Oncology
• 7.3 Neurology
• 7.4 Diabetes
• 7.5 Autoimmune diseases
• 7.6 Cardiology
• 7.7 Other indications

Chapter 8 Market Estimates & Forecast, By End Use, 2021-2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals and clinics
• 8.3 Pharmaceutical and biotechnology companies
• 8.4 Diagnostic labs
• 8.5 Other end users

Chapter 9 Market Estimates & Forecast, By Region, 2021-2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 MEA
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abbott Laboratories
• 10.2 Bio-Rad Laboratories
• 10.3 Danaher
• 10.4 EKF Diagnostics Holdings
• 10.5 F. Hoffmann-La Roche
• 10.6 Illumina
• 10.7 Lifesign
• 10.8 Merck
• 10.9 Myriad Genetics
• 10.10 QIAGEN
• 10.11 Signosis
• 10.12 Singulex
• 10.13 Thermo Fisher Scientific